Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wen-Chin Weng has a total of 258 co-authors. Here are the top co-authors by number of shared publications:

  • Wang-Tso Lee

    National Taiwan University College of Medicine, Taipei, Taiwan

    34 shared publications
  • Wei-Chung Hsu

    Department of Otolaryngology National Taiwan University Hospital and Children's Hospital Taipei Taiwan

    21 shared publications
  • Pei-Lin Lee

    Center of Sleep Disorder, National Taiwan University Hospital , Taipei

    18 shared publications
  • Kun-Tai Kang

    Department of Otolaryngology, National Taiwan University Hospital, Taipei, Taiwan; Department of Otolaryngology, Taipei Hospital, Ministry of Health and Welfare, New Taipei City, Taiwan; Institute of Health Policy and Management, National Taiwan University, Taipei, Taiwan

    11 shared publications
  • Wang-Tso Lee

    Department of Pediatrics, National Taiwan University Hospital, Taiwan; Division of Pediatric Neurology, Department of Pediatrics, National Taiwan University Children Hospital, Taiwan

    11 shared publications
  • Steven Shinn-Forng Peng

    Department of Nuclear Medicine, National Taiwan University Hospital, Taipei, Taiwan

    10 shared publications

Latest Publications

  • Open Access

    Updates of spinal muscular atrophy in advanced therapies

    by Wen-Chin Weng, Wang-Tso Lee, Yin-Hsiu Chien, Li-Kai Tsai


  • Open Access

    Machine learning to predict mitochondrial diseases by phenotypes

    by Chieh-Wen Kuo, Hui-An Chen, Rai-Hseng Hsu, Chao-Szu Wu, Ching Hsu, Ming-Jen Lee, Yin-Hsiu Chien, Hsueh-Wen Hsueh, Feng-Jung Yang, Pi-Chuan Fan, et al.


  • Mechanisms of functional improvement behind nusinersen treatment in adult spinal muscular atrophy

    by Pei-Feng Hsieh, Hsing-Jung Lai, Yih-Chih Kuo, Chih-Chao Yang, Po-Ya Huang, Chen-Hung Ting, Shao-Ting Tai, Chia-Hsin Kao, Yi-Chieh Tsai, Hsi-Wen Huang, et al.


  • Minimal to Mean Airway Area Ratio of the Pharynx: A Novel Predictor of Pediatric Obstructive Sleep Apnea in Three‐Dimensional Imaging

    by Kun‐Tai Kang, Yunn‐Jy Chen, Wen‐Chin Weng, Hung‐Ta Hsiao, Pei‐Lin Lee, Wei‐Chung Hsu

    Objective: Reliable variables for detecting pediatric obstructive sleep apnea (OSA) using three‐dimensional (3D) imaging are currently lacking. This study aimed to develop a novel predictor of OSA in children.Study Design: Prospective study.Setting: Tertiary care children's hospital.Methods: Pediatric patients ( 10). Cone‐beam computed tomography was used to obtain 3D images. The minimal to mean airway area (AA) ratio was measured across the entire pharynx and its segment (nasopharynx, oropharynx, and hypopharynx).Results: The study included 104 children. For the entire pharynx, the minimal to mean AA ratio was 0.41, 0.36, 0.35, and 0.25 in the primary snoring, mild OSA, moderate OSA, and severe OSA groups, respectively (P = .001). Pearson's correlation revealed an inverse relationship between the minimal to mean AA ratio and OSA severity. The receiver operating characteristic curve identified the optimal cutoff point for predicting AHI ≥ 1 as 0.34 in the oropharynx (area under the curve [AUC] = 71%) and 0.39 in the entire pharynx (AUC = 67%). The minimal to mean AA ratio in the nasopharynx or hypopharynx indicated no significant difference between OSA severities.Conclusion: A minimal to mean airway AA ratio of less than one‐third in the pharynx serves as a novel predictor of pediatric OSA in 3D imaging.


  • Radiomics with Ultrasound Radiofrequency Data for Improving Evaluation of Duchenne Muscular Dystrophy

    by Dong Yan, Qiang Li, Ya-Wen Chuang, Chia-Wei Lin, Jeng-Yi Shieh, Wen-Chin Weng, Po-Hsiang Tsui

    Duchenne muscular dystrophy (DMD) is a rare and severe genetic neuromuscular disease, characterized by rapid progression and high mortality, highlighting the need for accurate ambulatory function assessment tools. Ultrasound imaging methods have been widely used for quantitative analysis. Radiomics, which converts medical images into data, combined with machine learning (ML), offers a promising solution. This study is aimed at utilizing radiomics to analyze different stages of data generated during B-mode image processing to evaluate the ambulatory function of DMD patients. The study included 85 participants, categorized into ambulatory and non-ambulatory groups based on their functional status. Ultrasound scans were utilized to capture backscattered radiofrequency data, which were then processed to generate envelope, normalized, and B-mode images. Radiomics analysis involved the manual segmentation of grayscale images and automatic feature extraction using specialized software, followed by feature selection using the maximal relevance and minimal redundancy method. The selected features were input into five ML algorithms, with model evaluation conducted via area under the receiver operating characteristic curve (AUROC). To ensure robustness, both leave-one-out cross-validation and repeated data splitting methods were employed. Additionally, multiple ML models were constructed and tested to assess their performance. The intensity values across all image types increased as walking ability declined, with significant differences observed between the ambulatory and non-ambulatory groups (p < 0.001). These groups exhibited similar diagnostic performance levels, with AUROC values below 0.8. However, radiofrequency (RF) images outperformed other types when radiomics was applied, notably achieving an AUROC value of 0.906. Additionally, combining multiple ML algorithms yielded a higher AUROC value of 0.912 using RF images as input. Radiomics analysis of RF data surpasses conventional B-mode imaging and other ultrasound-derived images in evaluating ambulatory function in DMD. Moreover, integrating multiple machine learning models further enhances classification performance. The proposed method in this study offers a promising framework for improving the accuracy and reliability of clinical follow-up evaluations, supporting more effective management of DMD. The code is available at https://github.com/Goldenyan/radiomicsUS.


  • Open Access

    Optimizing DMD management in Asia: Current challenges and future directions

    by Wen-Chin Weng, Sophelia H.S. Chan, Roy Gomez, Furene Wang, Hsu-Wen Chou, Jocelyn Lim, Sarah Tsai, Ting Rong Hsu, Yuh-Jyh Jong

    Background: Since 1970, advances in Duchenne muscular dystrophy (DMD) management have significantly extended the patients’ life expectancy. However, DMD remains universally fatal. Objective: To understand the current DMD management standards and practices in Asia and to evaluate inconsistencies, unmet needs, and future directions for DMD patient management in the region. Methods: Clinical experts from Hong Kong, Singapore, and Taiwan convened in September 2023 to discuss DMD diagnosis, assessment, treatment, and management best practices. A pre-meeting survey was also administered to explore professional perspectives and practices and refine the discussion focus. Results: Genetic profiling has become the pivotal diagnostic tool and has been universally adopted by experts. Steroid therapy is recognized as the cornerstone of DMD care. However, there are various opinions regarding the timing of its initiation and whether it should be continued after the loss of ambulation. Gene therapy has the potential to significantly improve outcomes in patients with DMD. However, its adoption is hampered by high costs, the potential for serious adverse events, and difficulties with patient selection. Governments and manufacturers must work together to improve its affordability. Establishing a centralized DMD registry garnered strong support from the experts as it promised to provide insights into unique DMD subtypes, standardize treatment protocols, and facilitate the conduct of clinical trials. Furthermore, the introduction of gene therapy has highlighted the need for generating long-term safety and effectiveness data in patients with DMD. Lastly, a centralized patient registry can be used to inform policy decisions. Conclusions: DMD care in Asia is characterized by substantial heterogeneity, with financial and reimbursement issues playing a major role in management decisions. A centralized patient registry has the potential to address these concerns by providing a valuable source of information.

  • Open Access

    Recent Advance in Disease Modifying Therapies for Spinal Muscular Atrophy

    by Li-Kai Tsai, Chen-Hung Ting, Yo-Tsen Liu, Cheng-Tsung Hsiao, Wen-Chin Weng, Society For Neurological Rare Disorders-Taiwan

    Spinal muscular atrophy (SMA) is an autosomal recessive motor neuron disease characterized by progressive weakness and atrophy of skeletal muscles. With homozygous survival motor neuron 1 (SMN1) gene mutation, all SMA patients have at least one copy of the SMN2 gene, which provides an opportunity for drug targeting to enhance SMN expression. Current three disease modifying drugs, including nusinersen, onasemnogene abeparvovec, and risdiplam, have demonstrated impressive effectiveness in SMA treatment. Nusinersen is an antisense oligonucleotide targeting SMN2 pre-messenger RNA (mRNA) to modify alternative splicing and is effective in SMA children and adults, administrating via intermittent intrathecal injection. Onasemnogene abeparvovec is an adeno-associated viral vector carrying human SMN1 gene, featuring intravenous injection once in a lifetime for SMA patients less than 2 years of the age. Risdiplam is a small molecule also targeting SMN2 pre-mRNA and is effective in SMA children and adults with administration via oral intake once per day. Patients with SMA should receive these disease modifying therapies as soon as possible to not only stabilize disease progression, but potentially obtain neurological improvement. The development in these therapies has benefited patients with SMA and will potentially provide insight in future drug discovery for other neurodegenerative diseases.